NovaBridge Biosciences (NBP)
| Market Cap | 140.36M -74.1% |
| Revenue (ttm) | n/a |
| Net Income | -117.55M |
| EPS | -1.04 |
| Shares Out | 116.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 363,882 |
| Open | 1.260 |
| Previous Close | 1.260 |
| Day's Range | 1.195 - 1.280 |
| 52-Week Range | 1.190 - 5.190 |
| Beta | 1.60 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+643.8%) |
| Earnings Date | Aug 20, 2026 |
About NBP
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab a... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for NBP stock is "Strong Buy." The 12-month stock price target is $9.0, which is an increase of 643.80% from the latest price.
News
NovaBridge Biosciences Press release: FY 2026
NovaBridge Biosciences issued a press release on November 2, 2026, disclosing material business information to investors.
NovaBridge appoints Chuck Silberstein as CFO
NovaBridge (NBP) announced the appointment of Chuck Silberstein as CFO, effective November 2. Silberstein succeeds Kyler Lei, who is stepping down following a successful tenure with the company. Most ...
NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer
Biotechnology Executive Brings Extensive Capital Markets, Financing, Corporate Strategy and Investor Relations Experience Biotechnology Executive Brings Extensive Capital Markets, Financing, Corporate...
NovaBridge announces presentation of results from Phase 1b study of givastomig
NovaBridge (NBP) Biosciences announced the presentation of updated results from the ongoing Phase 1b study of givastomig, a CLDN18.2 x 4-1BB bispecific antibody, in combination with nivolumab and chem...
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesophageal adenocarcinoma...
Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia
YOL104-2 is a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic with the potential to be a first-in-class therapy for Ocular Surface Squamous Neoplasia (OSSN)
Wuhan Hiteck enters exclusive license agreement with Visara
Wuhan Hiteck Biological Pharma Co. announced that it has entered into an exclusive license agreement with Visara, a majority-owned ophthalmology subsidiary of NovaBridge (NBP) Biosciences, for HT006.2...
Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
Hiteck grants Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP), exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2 Hit...
Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
Visara secures exclusive worldwide rights, excluding Greater China, from Wuhan Hiteck Biological Pharma to develop and commercialize HT006.2.2 Visara plans to develop HT006.2.2 as VIS-102, its second ...
NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026
ROCKVILLE, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ: NBP) today announced that updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 (CLDN18.2)...
NovaBridge Biosciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The discussion highlighted a strategy of sourcing late-stage, de-risked assets globally, with lead programs givastomig and VIS-101 advancing in oncology and ophthalmology. Givastomig shows promise in low claudin expressers and is moving toward phase III, while VIS-101 aims for durable efficacy in AMD.
NovaBridge Biosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted progress on a bispecific therapy for gastric cancer, with phase III trials and potential expansion into pancreatic and biliary cancers. The company is also advancing an ophthalmology asset aiming for less frequent dosing, while exploring new opportunities in women's health and global markets.
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
ROCKVILLE, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and ap...
NovaBridge Biosciences to Participate in September Investor Conferences
ROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and app...
NovaBridge Biosciences Earnings Call Transcript: Q2 2026
Strong cash position and debt-free balance support advancement of lead programs givastomig and VIS-101, both progressing toward late-stage clinical milestones. Strategic focus includes disciplined capital allocation, European partnerships, and expansion into women's health.
NovaBridge Biosciences Earnings release: Q2 2026
NovaBridge Biosciences released its Q2 2026 earnings on August 20, 2026, summarizing the period's financial results.
NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution
ROCKVILLE, Md., Aug. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and app...
NovaBridge Biosciences Slides: Company presentation
NovaBridge Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and app...
NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
ROCKVILLE, Md., July 24, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for ar...
NovaBridge CEO Xi-Yong Fu to step down, Srishti Gupta to succeed
NovaBridge (NBP) announced the appointment of Srishti Gupta as CEO and a member of the company’s board of directors, effective July 1. Xi-Yong Fu will step down as CEO to…
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for ar...
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026 Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026 ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIR...
NovaBridge Biosciences Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted a robust pipeline in oncology and ophthalmology, with givastomig showing superior efficacy and safety in gastric cancer and VIS-101 demonstrating strong durability in wet AMD. Ample cash reserves support clinical milestones through 2028.
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative...